Compare WB & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WB | MLYS |
|---|---|---|
| Founded | 2009 | 2019 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.2B |
| IPO Year | 2014 | 2023 |
| Metric | WB | MLYS |
|---|---|---|
| Price | $8.69 | $28.29 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | $14.00 | ★ $48.67 |
| AVG Volume (30 Days) | 1.1M | ★ 1.3M |
| Earning Date | 05-20-2026 | 05-11-2026 |
| Dividend Yield | ★ 6.95% | N/A |
| EPS Growth | N/A | ★ 37.43 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $2.55 | N/A |
| Revenue Next Year | $1.94 | N/A |
| P/E Ratio | $5.66 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.10 | $10.44 |
| 52 Week High | $12.96 | $47.65 |
| Indicator | WB | MLYS |
|---|---|---|
| Relative Strength Index (RSI) | 34.36 | 58.05 |
| Support Level | $8.36 | $26.85 |
| Resistance Level | $10.51 | $31.09 |
| Average True Range (ATR) | 0.26 | 1.62 |
| MACD | 0.03 | 0.68 |
| Stochastic Oscillator | 35.75 | 87.49 |
Weibo Corp is a China-based company mainly engaged in the social media advertising business for people to create, discover and distribute content. The company's activities include Advertising and Marketing, which mainly provides a full range of advertising customization and marketing solutions. The Value-added Services mainly provide services such as membership services on social platforms, online games, live broadcasts, social e-commerce, and others. The Company's main product is the social platform Weibo.
Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone.